Similarly, a phase 2 study reported a 1-year PFS rate of 44.4% when radiotherapy plus the anti-PD-1 antibody camrelizumab were used as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma [162] (Table 1). The gene discussed is PDCD1; the disease is intrahepatic cholangiocarcinoma.